MK-212 has been used in trials studying the treatment of Alcoholism.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Hydrocodone | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Magnesium sulfate | The therapeutic efficacy of MK-212 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | MK-212 may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Orphenadrine | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Pramipexole | MK-212 may increase the sedative activities of Pramipexole. |
| Ropinirole | MK-212 may increase the sedative activities of Ropinirole. |
| Rotigotine | MK-212 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with MK-212. |
| Sodium oxybate | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Thalidomide | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with MK-212. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with MK-212. |
| Dicoumarol | The risk or severity of adverse effects can be increased when MK-212 is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when MK-212 is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when MK-212 is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when MK-212 is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when MK-212 is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when MK-212 is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when MK-212 is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when MK-212 is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when MK-212 is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when MK-212 is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when MK-212 is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when MK-212 is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when MK-212 is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when MK-212 is combined with (S)-Warfarin. |
| Mirtazapine | MK-212 may increase the serotonergic activities of Mirtazapine. |
| Ethanol | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | MK-212 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when MK-212 is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when MK-212 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when MK-212 is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when MK-212 is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when MK-212 is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when MK-212 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when MK-212 is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when MK-212 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when MK-212 is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when MK-212 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with MK-212. |
| Seproxetine | The risk or severity of adverse effects can be increased when MK-212 is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when MK-212 is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when MK-212 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when MK-212 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when MK-212 is combined with Alaproclate. |
| Methylene blue | MK-212 may increase the serotonergic activities of Methylene blue. |
| Zopiclone | The risk or severity of adverse effects can be increased when MK-212 is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with MK-212. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with MK-212. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with MK-212. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of MK-212. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with MK-212. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with MK-212. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with MK-212. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with MK-212. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with MK-212. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with MK-212. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with MK-212. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with MK-212. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with MK-212. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with MK-212. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with MK-212. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with MK-212. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with MK-212. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with MK-212. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with MK-212. |
| Venlafaxine | The risk or severity of serotonin syndrome can be increased when MK-212 is combined with Venlafaxine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with MK-212. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with MK-212. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with MK-212. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with MK-212. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with MK-212. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with MK-212. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with MK-212. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with MK-212. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with MK-212. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with MK-212. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with MK-212. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with MK-212. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with MK-212. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with MK-212. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with MK-212. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with MK-212. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with MK-212. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with MK-212. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with MK-212. |